View More Recent Stories

Feb 26, 2020 04:59PM Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019
Feb 25, 2020 06:00AM Mesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019
Feb 24, 2020 06:00AM Consistent Outcomes Using Ryoncil™ as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD
Feb 20, 2020 06:00AM Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease
Feb 3, 2020 06:00AM Mesoblast Submits Completed Biologics License Application for Ryoncil™ to US FDA
Feb 3, 2020 06:00AM Mesoblast Submits Completed Biologics License Application for Ryoncil™ to US FDA
Jan 15, 2020 06:00AM Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco
Jan 2, 2020 06:31AM Mesoblast (MESO) Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L
Jan 2, 2020 06:00AM Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L
Dec 18, 2019 06:00AM Data Monitoring Committee Completes Final Scheduled Review of Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure
Dec 17, 2019 06:00AM Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion
Nov 25, 2019 04:52PM Mesoblast Finanical Results for the Quarter Ended September 30, 2019
Nov 21, 2019 04:29PM Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019
Oct 16, 2019 06:17PM Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
Oct 3, 2019 07:59AM Mesoblast Completes Successful Institutional Capital Raising of A$75 Million
View More Recent Stories